Home>Topics>Stocks>Vertex Pharmaceuticals

Vertex Pharmaceuticals VRTX

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. Headlines
    1. Vertex Pharmaceuticals Incorporated's ( VRTX ) CEO Jeffrey Leiden on Q2 2014 Results - Earnings Call Transcript

      Headlines

      Tue, 29 Jul 2014

      Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) Q2 2014 Earnings Call July 29, 2014 5:00 pm ET Executives Michael Partridge - Senior Director of Strategic Communications

    2. Vertex sticks with prior guidance after Q2 results

      Headlines

      Tue, 29 Jul 2014

      Vertex Pharmaceuticals ( VRTX ) Q2 results : Total Revenues: $138.4M (-55.5%), Product Sales: $122.3M (-52.0%), Kalydeco Sales: $113

    3. Notable earnings after Tuesday's close

      Headlines

      Mon, 28 Jul 2014

      NCR , NEM , NEU , NFX , NTRI , NUVA , PEI , PLT , PNRA , QGEN , RBC , RGR , RKT , RNG , RNR , ROG , RPXC , RT , RUBI , SB , SLCA , SM , SQNM , TMH , TRN , TWTR , TX , UGI , ULTI , USNA , VRSK , VRTX , WNC , WSH , WTS , X , XCO , XPO 1 comment!

    4. Biotechs Have Their 'Irrational Exuberance' Moment: Time To Buy More?

      Headlines

      Mon, 21 Jul 2014

      By DoctoRx : Background : When the Fed noted some froth in "smaller" biotechs last week, large ones also got slammed. Biogen Idec (NASDAQ: BIIB ) fell more than 7% after that statement. Gilead Sciences (NASDAQ: GILD ) fell 5% peak-to-trough. Small ones got dumped big-time. Is it but a passing ...

    5. Vertex CSO retires

      Headlines

      Thu, 10 Jul 2014

      Vertex Pharmaceuticals ( VRTX ) EVP of Global R&D and Chief Scientific Officer Peter Mueller, Ph.D., announces his retirement effective October 31, 2014, following a planned transition period. Post your comment!

    6. Vertex applies for a label expansion for Kalydeco

      Headlines

      Mon, 30 Jun 2014

      Vertex Pharmaceuticals ( VRTX +1% ) files an sNDA with the FDA for the approval of Kalydeco (ivacaftor) as a treatment for cystic fibrosis (CF) in patients

    7. CHMP recommends label expansion for Kalydeco

      Headlines

      Fri, 27 Jun 2014

      Medicinal Products for Human Use (CHMP) recommends that the European Medicines Agency (EMA) approve Vertex Pharmaceuticals ' ( VRTX ) Kalydeco ( ivacaftor ) for cystic fibrosis (CF) patients ages six and older who have one of eight non

    8. Vertex Soars On Phase III Trial Results: Assessing The Upside Potential From Here

      Headlines

      Wed, 25 Jun 2014

      By DoctoRx: Background : Vertex Pharmaceuticals ( VRTX ) is one of a group of biotech/biopharma companies that focuses on oral medications, not injectable proteins. The company has

    9. Positive Results For Vertex Pharmaceuticals ; Ok Results For Structured Note Holders

      Headlines

      Wed, 25 Jun 2014

      This morning Vertex Pharmaceutical ( VRTX ) announced positive results for phase ..... with roughly $20 Million in notional on VRTX . As I wrote in my blog post on binary ..... with two unattractive outcomes - if the VRTX clinical trial was successful, the stock

    10. Midday Gainers / Losers

      Headlines

      Tue, 24 Jun 2014

      Top 10 Gainers: VRTX +40% . CRMD +33% . XGTI +32% . KONE +32% . NURO +25% . ISR +18% . MEET +17% . UBIC +16% . INWK +12% . SR +12

    « Prev12345Next »
    Content Partners